Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

• Main Authors: Joshua K. Kays (Author), Safi Shahda (Author), Melissa Stanley (Author), Teresa M. Bell (Author), Bert H. O'Neill (Author), Marc D. Kohli (Author), Marion E. Couch (Author), Leonidas G. Koniaris (Author), Teresa A. Zimmers (Author)
• Format: Book
• Published: Wiley, 2018-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5‐fluorouracil, leucovorin, irinotecan...